Recent news on Gliadel

MGI PHARMA to Present at the Bank of America Healthcare Conference  -  May 24, 2007
Insurance News Net,MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(R) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with

Aquavan(R) (Fospropofol Disodium) Injection Data Presented at ...  -  May 24, 2007
PipelineReview.com (press release),MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(R) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with

Brain cancer drugs approved in England  -  Apr 11, 2007
Science Daily (press release)Temodal and Gliadel may now be obtained through the National Health Service. The 2005 ban was based on cost-effectiveness.

MGI PHARMA Reports First Quarter 2007 Financial Results  -  Apr 19, 2007
PharmaLive.com (press release),Sales of Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) were $9.7 million for the first quarter of 2007, compared to $9.7 million in the first

NICE finally approves glioma drugs after finding error in its ...  -  Apr 17, 2007
Healthcare Equipment and Supplies,...the treatment of newly-diagnosed glioblastoma multiforme (GBM) as well as Link Pharmaceutical's Gliadel (carmustine implant) in a subgroup of patients.

Data from Investigator-Sponsored Trial of Oncophage(R) Cancer ...  -  Apr 16, 2007
PipelineReview.com (press release),Dr. Brem is a developer of Gliadel(R) Wafer (polifeprosan 20 with carmustine implant, MGI Pharma), the first approved local therapy for glioma.

MGI Pharma First Quarter 2007 Financial Results Conference Call to ...  -  Apr 11, 2007
PharmaLive.com (press release),MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(R) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with

MGI PHARMA First Quarter 2007 Financial Results Conference Call to ...  -  Apr 11, 2007
Business Wire (press release),MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen® (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine

Dr. Robert Langer Named as Chairman of Boston Life Sciences, Inc ...  -  Apr 5, 2007
Drug Newswire (press release),He is responsible for developing Gliadel from concept through preclinical and clinical trials and through FDA approval. Dr. Brem holds several patents for

Neopharm names new president, CEO  -  27 Mar 2007
BusinessWeekNeopharm was evaluating its cintredekin besudotox for the treatment of recurrent glioblastoma multiforme against an existing treatment called Gliadel Wafer,

Chemo wafers helping brain cancer patients live a better life  -  Mar 3, 2007
St. Petersburg Times,Izandick believes it was the dime-sized Gliadel Wafers, which contain chemotherapy that dissolves right onto the site of the tumor cavity after surgery and

NEOPHARM (NEOL) Reports Q4 Earnings, Provides Update on Status of ...  -  Mar 13, 2007
StreetInsider.com (subscription),...which was a statistically significant difference, or separation, in the overall survival curves versus the Gliadel Wafer®, or Gliadel.

MGI Pharma Announces Change to Presentation Date and Time at the ...  -  Mar 15, 2007
PharmaLive.com (press release),MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(R) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with

News For Your Web Site  -  Mar 15, 2007
dBusinessNews Minneapolis (press release),MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen® (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine

Dr. Robert Langer Named as Chairman of Boston Life Sciences, Inc ...  -  Mar 22, 2007
PR Newswire (press release),He is responsible for developing Gliadel from concept through preclinical and clinical trials and through FDA approval. Dr. Brem holds several patents for

MGI PHARMA Amends Quarterly Filings for Second and Third Quarters ...  -  Mar 1, 2007
Genetic Engineering News (press release),MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(R) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with

Evergreening is a global phenomenon  -  Feb 25, 2007
Economic Times,In yet another judgement, the European Court of Justice (ECJ) while upholding the German court ruling against SPC for chemotherapeutic Gliadel sought to

Eye On Cash-Rich Small Biotechs  -  Feb 27, 2007
Seeking Alpha,...a proposed treatment for brain tumors, failed to show statistically superior results compared to MGI Pharma’s (Nasdaq: MOGN) Gliadel Wafer.

MGI PHARMA Reports Fourth Quarter and Full Year 2006 Financial Results  -  Feb 8, 2007
PharmaLive.com (press release),Sales of Gliadel Wafer were $8.2 million for the fourth quarter of 2006, compared to $8.5 million in the fourth quarter of 2005. For the year ended December

Pharma Sector: Few Newsmakers Of The Week - Exelixis, MGI Pharma ...  -  Feb 3, 2007
Trading Markets,The regulatory agency stated that the two-page promotional ad for Gliadel Wafer, "fails to disclose its full indication and presents unsubstantiated claims"

FDA says MGI Pharma brain tumor ad misleading  -  Feb 1, 2007
Pharmaceutical Business ReviewThe FDA has judged that an advert made by MGI Pharma to promote its brain cancer product Gliadel Wafer is misleading, according to a letter released by the

MGI Pharma ordered to halt misleading ad  -  Jan 31, 2007
Minneapolis Star Tribune (subscription),The ad makes claims such as "Take the Path to Avoid Treatment Delays," and "Gliadel Wafer Works at Day 1." The FDA, in an undated letter to the company,

FDA: Brain Drug Ad 'Misleading'  -  Jan 31, 2007
Smartmoney.comThe advertisement in question involved the company's Gliadel Wafer, which is a dissolvable wafer implanted in the brain following surgery to remove a tumor.

MGI Pharma cited by FDA for "misleading" advertising  -  Jan 31, 2007
Bizjournals.com,The FDA said a two-page promotional ad for the product, called Gliadel Wafer, "fails to disclose its full indication and presents unsubstantiated claims".

Boston Life Sciences Announces the Appointment of Henry Brem, MD ...  -  Feb 6, 2007
PR Newswire (press release),He is responsible for developing Gliadel(R) wafer, a brain cancer treatment, from concept through FDA approval. Dr. Brem holds several patents for

MGI Pharma and Helsinn Healthcare SA Announce Patent Extension for ...  -  Feb 13, 2007
PharmaLive.com (press release),MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(R) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with

PUBLIC COMPANY NEWS  -  Feb 4, 2007
Pioneer Press,MGI Pharma (Nasdaq: MOGN): Agreed to pull a trade journal advertisement for its Gliadel Wafer chemotherapy treatment after the Food and Drug Administration

US Bancorp sells debt to fund stock buyback  -  Feb 1, 2007
Pioneer Press,The two-page promotional ad for the company's Gliadel Wafer product failed to disclose the full indication for the drug, and presented unsubstantiated

MGI PHARMA to Present at the 2007 Merrill Lynch Global ...  -  Jan 31, 2007
dBusinessNews Minneapolis (press release),MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen™ (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine

MGI Pharma Fourth Quarter and Year End 2006 Financial Results ...  -  Jan 31, 2007
PharmaLive.com (press release),MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with

MGI Pharma Announces Publication of Phase 3 Data for Saforis ...  -  18 Jan 2007
PharmaLive.com (press release),MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with

Targepeutics Actively Developing Targeted Molecular Therapies For ...  -  Jan 7, 2007
Medical News Today (press release),...(Cintredekin Besudotox) was at least as potent as MGI Pharma's Gliadel Wafer in patients with treatment- resistant recurrent high-grade astrocytoma.

MGI Pharma Announces Publication of Phase 2 Data Describing ...  -  Jan 3, 2007
PharmaLive.com (press release),MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with

JPMorgan 25th Annual Healthcare Conference  -  Jan 3, 2007
Business Wire (press release),MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen™ (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine

NeoPharm takes turn for worse  -  Dec 12, 2006
Chicago Sun-Times,Median survival was 36.4 weeks for patients treated with cintredekin besudotox, compared with 35.3 weeks for those treated with the Gliadel Wafer.

Analysts sour on NeoPharm  -  Dec 13, 2006
Monsters and Critics.com,In the PRECISE trial, median survival in the cintredekin group was 36.4 weeks compared with 35.3 weeks in the Gliadel group.

NEOPHARM Announces Efficacy Results for Phase 3 PRECISE Trial  -  Dec 12, 2006
PipelineReview.com (press release),..."Topline data suggests that cintredekin besudotox, while comparable, was not statistically superior to Gliadel," said Guillermo A. Herrera, President and

NeoPharm drug fails late-stage cancer test  -  Dec 12, 2006
Chicago Daily Herald (subscription),...“The apparent shrinking of CBtox’s commercial opportunity to the size of Gliadel’s $35 million argues against that expense,� Webber wrote.

NeoPharm drug misses goal in trial, stock plunges  -  Dec 11, 2006
Reuters..."Topline data suggests that cintredekin besudotox, while comparable, was not statistically superior to Gliadel," Guillermo Herrera, NeoPharm's chief

NeoPharm drug fails test  -  Dec 12, 2006
Chicago Tribune,In the trial involving about 300 patients, about two-thirds received IL-13 and the remaining one-third received Gliadel Wafer, the standard chemotherapy

Health Winners & Losers  -  Dec 11, 2006
TheStreet.comGliadel was approved in 1997 to treat brain cancer by delivering the drug directly to the tumor. Shares of Kosan Biosciences (KOSN - commentary - Cramer's

NeoPharm drug falls short  -  Dec 12, 2006
Waukegan News Sun,The goal was a statistically significant difference in overall survival rates between the drug and Gliadel Wafer, an existing drug from MGI Pharma Inc. of

NeoPharm off more than 70% after drug misses target  -  Dec 11, 2006
Crain's Chicago Business,...the most common form of malignant brain cancer. The median survival time for NeoPharm's drug was 36.4 weeks, compared with 35.3 weeks for Gliadel Wafer.

NeoPharm "neutral," target price reduced  -  Dec 12, 2006
newratings.com...mention that the company has announced that its Phase 3 PRECISE trial for cintredekin besudotox (IL-13) has failed to show better efficacy than Gliadel.

NeoPharm shares tumble on news of disappointing cancer drug trial  -  Dec 11, 2006
Chicago Tribune,The median survival rate for patients on the new drug, NeoPharm's cintredekin besudotox, was 36.3 weeks compared with 35.3 weeks for Gliadel Wafer,

Neopharm tumor drug trial fails  -  Dec 11, 2006
BusinessWeekThe company said it was evaluating cintredekin besudotox for the treatment of recurrent glioblastoma mulitforme against Gliadel Wafer, which is implanted in

Neopharm Inc. Is Falling On Disappointing Phase III News  -  Dec 11, 2006
Trading Markets,...efficacy endpoint at 215 deaths, which was a statistically significant difference, or separation, in the overall survival curves versus Gliadel Wafer.

Pharma Sector: Few Newsmakers Of The Week - Merck, Pfizer ...  -  Dec 15, 2006
Trading Markets,Gliadel was approved by the FDA in September 1996 to treat brain cancer by delivering the drug directly to the tumor. With not much of an exciting pipeline

MGI PHARMA and HELSINN Announce Positive Phase 3 Results for Aloxi ...  -  Dec 15, 2006
PipelineReview.com (press release),MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with

MGI PHARMA and HELSINN Announce Positive Phase 3 Results for Aloxi ...  -  Dec 14, 2006
Business Wire (press release),MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen™ (decitabine) for Injection, and Gliadel® Wafer (polifeprosan 20 with carmustine

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional